An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs

• DOI: 10.1186/s12985-022-01919-7
• Publication Date: 2022-11-12T10:02:58Z
• Authors: Jianglong Li; Qi Liu; Jun Liu; Xiaohong Wu; Yixin Lei; Shuang Li; Danhua Zhao; Zhi Li; Liping Luo; Sophia Peng; Yingrao Ou; Hong Yang; Jing Jin; Yuhua Li; Yucai Peng
• Keywords: Duck embryo vaccine; Rabies vaccine

Abstract Rabies is a lethal zoonotic disease that mainly caused by the rabies virus (RABV). Although effective vaccines have long existed, current take both time and cost to produce. Messenger RNA (mRNA) technology an emergent vaccine platform supports rapid development on large scale. Here, optimized mRNA construct (LVRNA001) expressing glycoprotein (RABV-G) was developed in vitro then evaluated vivo for its immunogenicity protective capacity mice dogs. LVRNA001 induced neutralizing antibody production strong Th1 cellular immune response mice. In dogs, provided protection against challenge with 50-fold dose 50 (LD ) of RABV. With regards efficiency, extended dosing interval (14 days) greater than 3- or 7-day intervals Finally, post-exposure immunization RABV performed evaluate survival rates dogs receiving two 25 μg doses vs. five inactivated over course three months. Survival rate group 100%, whereas control only 33.33%. conclusion, these results demonstrated responses which provides new promising prophylactic strategy rabies.